[1]AL-KAMEL HAITHM ALI MOHAMMED HASAN,迟宝进.炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效的预测研究[J].医学信息,2025,38(01):117-120.[doi:10.3969/j.issn.1006-1959.2025.01.022]
　AL-KAMEL HAITHM ALI MOHAMMED HASAN,CHI Baojin.Predictive Study of Inflammatory Markers on the Efficacy of Different Neoadjuvant Therapy Regimens in Patients with Muscle-invasive Bladder Cancer[J].Journal of Medical Information,2025,38(01):117-120.[doi:10.3969/j.issn.1006-1959.2025.01.022]
点击复制

炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效的预测研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年01期
页码:
117-120
栏目:
论著
出版日期:
2025-01-01

文章信息/Info

Title:
Predictive Study of Inflammatory Markers on the Efficacy of Different Neoadjuvant Therapy Regimens in Patients with Muscle-invasive Bladder Cancer
文章编号:
1006-1959（2025）01-0117-04
作者:
AL-KAMEL HAITHM ALI MOHAMMED HASAN; 迟宝进
佳木斯大学附属第一医院泌尿外科，黑龙江 佳木斯 154003
Author(s):
AL-KAMEL HAITHM ALI MOHAMMED HASAN;  CHI Baojin
Department of Urology, the First Affiliated Hospital of Jiamusi University, Jiamusi 154003, Heilongjiang, China
关键词:
炎症标志物; 肌层浸润性膀胱癌; 辅助治疗方案; 疗效预测
Keywords:
Inflammatory markers;  Muscle-invasive bladder cancer;  Adjuvant therapy;  Efficacy prediction
分类号:
R737.14
DOI:
10.3969/j.issn.1006-1959.2025.01.022
文献标志码:
A
摘要:
目的 研究炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效的预测价值。方法 选取2022年5月-2023年5月在我院诊治的62例肌层浸润性膀胱癌患者为研究对象，分析中性粒细胞与淋巴细胞比值（NLR）、全身免疫炎症指数（SII）、血小板与淋巴细胞比值（PLR）炎症标志物对新辅助治疗效果的影响，依据最佳分界值将其分为高、低组，观察不同组间患者临床资料特点、病理参数及不同新辅助治疗的效果，进一步分析炎症指标高、低对患者接受新辅助治疗效果的影响。结果 NLR、SII、PLR高、低组患者性别、年龄、分期、肿瘤数量、发病情况比较，差异无统计学意义（P＞0.05）；新辅助治疗NLR、SII、PLR高、低组患者的客观缓解率（ORR）、疾病控制率（DCR）比较，差异有统计学意义（P＜0.05），且炎症指标比值越高，ORR、DCR更低（P＜0.05）；不同新辅助治疗方案的临床疗效比较，差异无统计学意义（P＞0.05）。结论 NLR、SII、PLR对肌层浸润性膀胱癌患者接受不同新辅助治疗方案的疗效具有一定的预测作用，且以上炎性指标比值越高，ORR、DCR更低，患者临床预后可能差，其对临床肌层浸润性膀胱癌新辅助治疗具有一定的参考价值。
Abstract:
Objective To study the predictive value of inflammatory markers for the efficacy of different neoadjuvant therapies in patients with muscle-invasive bladder cancer. Methods A total of 62 patients with muscle-invasive bladder cancer diagnosed and treated in our hospital from May 2022 to May 2023 were selected as the research objects. The effects of neutrophil-to-lymphocyte ratio (NLR), systemic immune inflammation index (SII), platelet-to-lymphocyte ratio (PLR) inflammatory markers on the efficacy of neoadjuvant therapy were analyzed. According to the optimal cut-off value, they were divided into high and low groups. The clinical data characteristics, pathological parameters and the effects of different neoadjuvant therapies were observed in different groups, and the effects of high and low inflammatory markers on the efficacy of neoadjuvant therapy were further analyzed. Results There was no significant difference in gender, age, stage, tumor number and incidence between the high and low groups of NLR, SII and PLR (P>0.05). There were statistically significant differences in the objective response rate (ORR) and disease control rate (DCR) between the high and low groups of NLR, SII and PLR in neoadjuvant therapy (P<0.05), and the higher the ratio of inflammatory indicators, the lower the ORR and DCR (P<0.05). There was no significant difference in the clinical efficacy of different neoadjuvant treatment regimens (P>0.05). Conclusion NLR, SII, and PLR have a certain predictive effect on the efficacy of different neoadjuvant therapy regimens in patients with muscle-invasive bladder cancer, and the higher the ratio of the above inflammatory indicators, the lower the ORR and DCR, and the clinical prognosis of patients may be poor. It has certain reference value for clinical neoadjuvant therapy of muscle-invasive bladder cancer.

参考文献/References:

[1]夏儒锐,梁培育,王声兴,等.新辅助化疗后行根治性切除术治疗局部转移性膀胱癌疗效分析[J].中华实用诊断与治疗杂志,2020,34(11):1092-1095.[2]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.[3]李靖,王斌,张震,等.膀胱灌注流量及膀胱充盈程度在膀胱热灌注化疗中的应用[J].实用医学杂志,2020,36(15):2167-2169.[4]郭学敬,王民,师磊,等.老年高危非肌层浸润性膀胱癌患者 TURBt 后即刻吉西他滨膀胱热灌注与常温灌注化疗的临床观察[J].临床泌尿外科杂志,2018,33(10):821-824.[5]张媚媚,李靖,庞廷媛,等.盐酸吉西他滨用于膀胱热灌注的药物稳定性研究[J].中国医院药学杂志,2022,42(16):1673-1679.[6]李波,杨雷,蒲麟龙,等.炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效预测分析[J].重庆医科大学学报,2023,48(8):880-883.[7]Li JZ,Cao DH,Huang Y,et al.The prognostic and clinicopathological significance of systemic immune-inflammation index in bladder cancer[J].Front Immunol,2022,13:865643.[8]陈思婷,张瑞丽,热米拉·艾海提,等.肌层浸润性膀胱癌新辅助化疗前后肿瘤浸润淋巴细胞标志物表达与化疗疗效相关性[J].中华实用诊断与治疗杂志,2022,36(10):1068-1070.[9]石洁,高琲,杨勇毅,等.围术期去除白细胞的红细胞输注减轻输血对膀胱癌患者的免疫抑制[J].细胞与分子免疫学杂志,2018,34(7):632-636.[10]韩健乐,杨帅平,王晓勃.Pyk2蛋白在非肌层浸润性膀胱癌中的表达及与该肿瘤预后的相关性[J].实用癌症杂志,2021,25(4):671-674.[11]陈思阳,丰琅,杜源,等.经尿道针状电极膀胱肿瘤整块切除术与经尿道钬激光膀胱肿瘤切除术治疗非肌层浸润性膀胱癌的治疗效果和安全性比较[J].首都医科大学学报,2018,39(3):439-443.[12]Zhou L,Xu HY,Li SM,et al.Study RC48-C014:Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma[J].J Clin Oncol,2022,40(Suppl 6):515.[13]吴维康,佟明.术前炎症细胞比值对非肌层浸润型膀胱癌预后的影响[J].锦州医科大学学报,2023,44(1):42-48.[14]Shah MA,Rogoff HA.Implications of reactive oxygen species on cancer formation and its treatment[J].Semin Oncol,2021,48(3):238-245.[15]王晶,丁雪丽,田字彬.术前全身炎症反应指数及预后营养指数对表浅型食管鳞癌患者预后的预测价值[J].世界华人消化杂志,2023,31(9):369-376.[16]朱梦柳,陈力,孔祥溢,等.全身炎症反应指数(SIRI)在乳腺癌患者中的临床意义和预后价值[J].现代肿瘤医学,2022,30(3):442-450.[17]田鑫,赵辉,王志强,等.全身炎症反应指数对老年非肌层浸润性膀胱癌患者的预后价值[J].现代泌尿外科杂志,2021,26(6):495-499.[18]杜君,段鹏强,张超,等.术前全身炎症反应指数对中高危非肌层浸润性膀胱癌预后的影响[J].中国肿瘤临床,2023,16(4):829-831.[19]曹志文,宋东奎,魏晓,等.术前全身免疫炎症指数对非肌层浸润性膀胱癌患者肿瘤复发的预测价值[J].天津医药,2021,15(2):355-357.[20]李攀,王博文一,洪星磊,等.术前系统免疫炎症指数对非肌层浸润性膀胱癌预后的评估价值[J].肿瘤基础与临床,2022,20(2):90-93

相似文献/References:

[1]丁 雪,刘海燕,胡安群,等.COVID-19与普通病毒性肺炎的临床特征分析[J].医学信息,2020,33(20):50.[doi:10.3969/j.issn.1006-1959.2020.20.014]
　DING Xue,LIU Hai-yan,HU An-qun,et al.Analysis of Clinical Characteristics of COVID-19 and Common Viral Pneumonia[J].Journal of Medical Information,2020,33(01):50.[doi:10.3969/j.issn.1006-1959.2020.20.014]

更新日期/Last Update: 1900-01-01